Virology News and Research

Latest Virology News and Research

Researchers develop technology to preserve vaccines in tropical temperatures

A team of British researchers have developed a simple, low-cost method to preserve vaccines in tropical climates, which they say could help to revolutionalize vaccination campaigns in developing countries, Reuters reports.

19 Feb 2010

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

Since the brain-injuring virus needs mosquitoes and pigs to spread, government officials should ban standing water in cemetery cisterns and urban drainage ditches. They should keep industrial "piggeries" away from cities and their populations.

19 Feb 2010

WHO recommends H1N1 be added to next year's seasonal flu virus

The WHO is recommending the H1N1 (swine flu) virus be added to the regular flu vaccine for the Northern Hemisphere's 2010-2011 regular flu season, the Associated Press reports (2/18).

19 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

Gene study could pave way for novel methods for plagues and other infectious diseases

An international consortium of scientists, including Universitat Aut-noma de Barcelona (UAB) researcher Deodoro Oliveira, have sequenced the genome of three species of parasitoid wasps of the genus Nasonia.

18 Feb 2010

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

Duke University Medical Center scientists crowded around a laser-powered microscope in a darkened room to peer into the brain of an anesthetized juvenile songbird right after he heard an adult tutors' song for the first time.

18 Feb 2010

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Pharmasset, Inc. announced today the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset.

17 Feb 2010

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Talecris Biotherapeutics announced today that it has received approval from Health Canada for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN® produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

17 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

XMRV infection is not linked to chronic fatigue syndrome

Researchers investigating UK samples have found no association between the controversial xenotropic murine leukaemia virus-related virus (XMRV) and chronic fatigue syndrome (CFS).

17 Feb 2010

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

Immune Targeting Systems (ITS) Limited (“ITS”), one of the leading developers of synthetic vaccines for mutating viruses, today announced it had secured a Series-A equity funding round extension for £8.65m which brings the total Series A financing to £13.15m. The company’s key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France) are all participating. The round will be kept open until mid-2010 for new potential investors to invest.

17 Feb 2010

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

Iowa State University researchers have so far won 30 grants worth a total $16.38 million from federal agencies awarding money from the American Recovery and Reinvestment Act (ARRA).

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

New program launched for HIV-positive men

The nation's largest surrogacy agency announced today that the number of babies born to HIV-positive clients is expected to more than double in 2010 as its program for HIV-positive men using their own sperm to create embryos continues to expand in the U.S. and abroad.

16 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Study: sdNVP can lead to HIV treatment failure in women receiving drug to prevent infant infection

A new international study reported in PLoS Medicine confirms that a single dose of nevirapine (sdNVP) can lead to HIV treatment failure in women who receive the drug to prevent transmission of the AIDS virus to their infants. However, the increased risk of failure could only be detected in women who began full HIV treatment within about a year after receiving sdNVP.

16 Feb 2010

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Oncogenic retroviruses are a particular family of viruses that can cause some types of cancer. Thierry Heidmann and his colleagues in the CNRS-Institut Gustave Roussy-Université Paris Sud 11 "Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs" Laboratory have studied these viruses. They have identified a "virulence factor" that inhibits the host immune response and allows the virus to spread throughout the body.

16 Feb 2010

Medivir, Meda announce agreement to commercialize Medivir’s cold sore product, Xerese

Medivir and Meda today announced an agreement for the commercialization of Medivir’s cold sore product which will be marketed in North America under the trade name Xerese™.

15 Feb 2010

WHO will meet to decide if H1N1 has peaked

The WHO will convene a meeting of its emergency committee later this month to assess whether H1N1 (swine flu) has peaked, Keiji Fukuda, the special adviser to the WHO's director general for pandemic influenza, said Thursday, Bloomberg reports.

15 Feb 2010

Virology News and Research

Latest Virology News and Research

Researchers develop technology to preserve vaccines in tropical temperatures

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

WHO recommends H1N1 be added to next year's seasonal flu virus

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Viral infection can suppress immune response to secondary bacterial infection

Gene study could pave way for novel methods for plagues and other infectious diseases

Neuroimaging study may lead to new therapeutic treatments for stroke and hearing loss

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

XMRV infection is not linked to chronic fatigue syndrome

ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study

Iowa State University researchers awarded 30 ARRA grants worth $16.38M

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

New program launched for HIV-positive men

Merck announces global sales of $27.4 billion for full-year 2009

Study: sdNVP can lead to HIV treatment failure in women receiving drug to prevent infant infection

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Medivir, Meda announce agreement to commercialize Medivir’s cold sore product, Xerese

WHO will meet to decide if H1N1 has peaked

Innovation in neuroscience drug discovery - eBook eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics